Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells

BACKGROUND: Ibrutinib is a Bruton’s tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK) inhibitor used for treating chronic lymphocytic leukaemia (CLL) and other cancers. Although ibrutinib is known to inhibit the growth of breast cancer cell growth in vitro, its impact on the treatment a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Varikuti, Sanjay, Singh, Bhawana, Volpedo, Greta, Ahirwar, Dinesh K., Jha, Bijay K., Saljoughian, Noushin, Viana, Agostinho G., Verma, Chaitenya, Hamza, Omar, Halsey, Gregory, Holcomb, Erin A., Maryala, Ritvik J., Oghumu, Steve, Ganju, Ramesh K., Satoskar, Abhay R.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7109110/
https://ncbi.nlm.nih.gov/pubmed/32025027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0743-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars